NCT00514228View on ClinicalTrials.gov

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

February 28, 2009

Conditions
Liver Cancer
Interventions
DRUG

sunitinib malate

"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"

Trial Locations (1)

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00514228 - Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter